A melanocortin receptor agonist approved in 2019 as Vyleesi for acquired low sexual desire in premenopausal women.
PT-141 is the research code for bremelanotide, a peptide that acts on melanocortin receptors in the brain. It was developed from Melanotan II. Unlike most peptides in this guide, it has an approved form: Vyleesi, an as-needed autoinjector.
FDA approved bremelanotide as Vyleesi in June 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. It is a prescription drug. Products sold online as "PT-141" are not Vyleesi.
Status reflects public FDA actions and reporting as of October 8, 2026. An advisory committee vote is a recommendation, not an FDA decision, and inclusion on a compounding list is not FDA approval.
FDA approval rested on two phase 3 trials (RECONNECT) in premenopausal women with hypoactive sexual desire disorder, which showed modest improvements in desire and related distress compared with placebo. Evidence for other uses, including in men, comes from earlier and smaller studies.
nnng.com does not publish doses, cycles or protocols for peptides. For approved drugs, the dose comes from the FDA-approved prescribing information and your prescriber. For unapproved compounds there is no established human dose, and numbers that circulate online are usually extrapolated from animal studies or written by sellers. If a clinician has already prescribed a dose, our reconstitution calculator converts that prescribed amount into syringe units. It is arithmetic only and does not suggest a dose.